Editorial: Overcoming resistance to immune checkpoint inhibitors: mechanisms and strategies in cancer therapy - Top-Institutions - MDSpire

Editorial: Overcoming resistance to immune checkpoint inhibitors: mechanisms and strategies in cancer therapy

  • By

  • Margherita Piccinelli

  • Elio Gregory Pizzutilo

  • Maria Gemelli

  • Dhifaf Sarhan

  • Stefano Cavalieri

  • May 6, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    University of Milan
    University of Milan

    Milan, Italy

    Key Differentiators

    • Oncology

  • #4

    European Institute of Oncology
    European Institute of Oncology

    Milan, Italy

    Key Differentiators

    • Oncology

Original Source(s)

Editorial: Overcoming resistance to immune checkpoint inhibitors: mechanisms and strategies in cancer therapy

  • by Margherita Piccinelli, Elio Gregory Pizzutilo, Maria Gemelli, Dhifaf Sarhan, Stefano Cavalieri

  • May 6, 2026

Related Content

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...